ECSP066507A - Moduladores de la p-selectina glicoproteina ligando psgl- i - Google Patents

Moduladores de la p-selectina glicoproteina ligando psgl- i

Info

Publication number
ECSP066507A
ECSP066507A EC2006006507A ECSP066507A ECSP066507A EC SP066507 A ECSP066507 A EC SP066507A EC 2006006507 A EC2006006507 A EC 2006006507A EC SP066507 A ECSP066507 A EC SP066507A EC SP066507 A ECSP066507 A EC SP066507A
Authority
EC
Ecuador
Prior art keywords
cell
glicoprotein
selectine
modulators
cells
Prior art date
Application number
EC2006006507A
Other languages
English (en)
Spanish (es)
Inventor
Rong-Hwa Lin
Chung Nan Chang
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/662,906 external-priority patent/US20040116333A1/en
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Publication of ECSP066507A publication Critical patent/ECSP066507A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EC2006006507A 2003-09-15 2006-04-13 Moduladores de la p-selectina glicoproteina ligando psgl- i ECSP066507A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/662,906 US20040116333A1 (en) 2001-08-03 2003-09-15 Modulators of P-selectin glycoprotein ligand 1

Publications (1)

Publication Number Publication Date
ECSP066507A true ECSP066507A (es) 2006-10-10

Family

ID=36242362

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006507A ECSP066507A (es) 2003-09-15 2006-04-13 Moduladores de la p-selectina glicoproteina ligando psgl- i

Country Status (16)

Country Link
EP (1) EP1663290A4 (fr)
JP (1) JP5808879B2 (fr)
KR (1) KR101159140B1 (fr)
CN (1) CN1852730B (fr)
AU (1) AU2004273807B2 (fr)
BR (1) BRPI0414402A (fr)
CA (1) CA2538284C (fr)
EC (1) ECSP066507A (fr)
IL (1) IL174172A (fr)
NO (1) NO20061306L (fr)
NZ (1) NZ546203A (fr)
RU (1) RU2407539C2 (fr)
SG (1) SG146670A1 (fr)
TW (2) TW201012472A (fr)
UA (1) UA91004C2 (fr)
ZA (1) ZA200602151B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510561A (pt) * 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
WO2009139459A1 (fr) * 2008-05-15 2009-11-19 国立大学法人 岡山大学 Procédé pour la prévention et le traitement du syndrome métabolique par l'inhibition de psgl-1
WO2017120534A1 (fr) * 2016-01-08 2017-07-13 Bioalliance C.V. Anticorps tétravalents contre psgl-1 et utilisations de ces derniers
CN115887659A (zh) * 2022-11-23 2023-04-04 中山大学附属第七医院(深圳) 终末耗竭t细胞群“tcf19+pd1+tim3+cd8+”的鉴定及应用
CN121108302A (zh) * 2025-09-22 2025-12-12 渼达(广州)生物科技有限公司 一种重组人Fc和P-选择素的重组蛋白、检测产品及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A7 (fi) * 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
ZA973051B (en) * 1996-04-24 1998-10-12 Genentech Inc Type c lectins
US6117977A (en) * 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies

Also Published As

Publication number Publication date
NZ546203A (en) 2009-05-31
JP5808879B2 (ja) 2015-11-10
UA91004C2 (uk) 2010-06-25
RU2407539C2 (ru) 2010-12-27
TW201012472A (en) 2010-04-01
IL174172A (en) 2011-12-29
KR20060088104A (ko) 2006-08-03
RU2006112399A (ru) 2006-08-10
TW200513262A (en) 2005-04-16
CN1852730B (zh) 2012-05-30
AU2004273807B2 (en) 2011-06-09
NO20061306L (no) 2006-06-14
BRPI0414402A (pt) 2006-11-14
CN1852730A (zh) 2006-10-25
CA2538284C (fr) 2015-10-20
IL174172A0 (en) 2006-08-01
CA2538284A1 (fr) 2005-03-31
JP2007533618A (ja) 2007-11-22
TWI359024B (en) 2012-03-01
AU2004273807A1 (en) 2005-03-31
ZA200602151B (en) 2013-08-28
EP1663290A2 (fr) 2006-06-07
EP1663290A4 (fr) 2009-07-01
KR101159140B1 (ko) 2012-06-22
SG146670A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
CY1108701T1 (el) Ρυθμιστες του γλυκοπρωτεϊνικου προσδεματος 1 της ρ-σελεκτινης.
MX2019011514A (es) Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
CY1119097T1 (el) Σιωπηλες παραλλαγες fc των anti-cd40 αντισωματων
MX2019002288A (es) Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores.
AR120563A1 (es) Receptores de antígeno quimérico cd19 y cd22 y sus usos
MX2021010670A (es) Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
AR111625A1 (es) Reactivos de partículas oligoméricas y métodos de uso de los mismos
UY30732A1 (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
MX2022011003A (es) Expansion de celulas t gamma-delta residentes en tejido no hematopoyetico y usos de estas celulas.
BR112019005633A8 (pt) Tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos
CU20110096A7 (es) Compuestos que expanden las células madre hematopoyéticas
CO6501191A2 (es) Medio de cultivo celular para expresión de la proteina adamts
MA38308A1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
PE20110020A1 (es) Inmunomodulacion mediante el uso de celulas madres de la placenta
EA201591467A1 (ru) Анти-lag-3 связывающие белки
PE20152005A1 (es) Dominios gla como agentes terapeuticos
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
ECSP099688A (es) Moléculas y métodos para modular la pro-proteína
MX2017016486A (es) Composiciones y metodos para controlar plagas vegetales.
EA201591373A1 (ru) Изготовление модифицированных внеклеточным матриксом тканеинженерных нервных трансплантатов для восстановления поврежденных периферических нервов
MX386373B (es) Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.
CL2017001903A1 (es) Composición novedosa para uso en el incremento de eficacia de injerto de células madre hematopoyéticas después del trasplante
MX2024004122A (es) Células citolíticas (asesinas) naturales y métodos de uso de las mismas.
BRPI0414402A (pt) moduladores de ligante 1 de glicoproteìna p-selectina
ECSP067055A (es) Epitopos inductores de muerte de celulas-t